Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the <scp>SERENA</scp> study

Abstract

Secukinumab showed high treatment persistence, sustained effectiveness and a favourable safety profile up to 3 years of follow-up in the real-world population of PsO patients observed in SERENA.